Goldman Sachs’s Terns Pharmaceuticals TERN Stock Holding History

Goldman Sachs’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.27M	Buy	+100,000	New	+$4.11M	﹤0.01%	3643

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Goldman Sachs's TERN Position: Q1 2026 in Review

Goldman Sachs increased its Terns Pharmaceuticals (TERN) stake by 4.1% in Q1 2026, buying an estimated $1.81M and bringing the position to 1,106,961 shares worth $58.4M. The position accounts for 0.01% of the portfolio, ranked #1458.

Goldman Sachs first reported a position in TERN in Q4 2021 and has held it in 18 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Goldman Sachs held 1,106,961 shares of Terns Pharmaceuticals worth $58.4M as of Q1 2026.
Goldman Sachs bought 43,977 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.81M.
Terns Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1458 holding.
Goldman Sachs first reported a position in Terns Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.